All News

Found 667 articles

• Ohr Pharmaceutical Initiates Phase II Trial of Squalamine Eye Drops for the Treatment of Wet Macular Degeneration

  9/24/2012

• Ohr Pharmaceutical to Present at The Rodman & Renshaw Annual Global Investment Conference

  9/6/2012

• FDA Approves Sanofi (France)-Regeneron Pharmaceuticals, Inc.'s Zaltrap for Metastatic Colorectal Cancer

  8/6/2012

• Ohr Pharmaceutical Issues Letter to Shareholders

  7/31/2012

• Roche's Lucentis Works to Treat Vision Loss from Diabetes

  7/25/2012

• Ohr Pharmaceutical Announces Positive Preclinical Safety Study Results for Squalamine Eye Drop for Wet-AMD

  7/10/2012

• Ohr Pharmaceutical Announces Squalamine Eye Drop Presentation by Dr. Michael Elman at Macula Society 2012

  6/15/2012

• Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board

  6/7/2012

• Intellect Neurosciences, Inc. Issues Letter to Shareholders

  5/15/2012

• FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD

  5/14/2012

• Ohr Pharmaceutical Presents Biodistribution and Safety Data on Squalamine Eye Drops at Association for Research in Vision & Ophthalmology 2012 Annual Meeting

  5/7/2012

• Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant

  5/3/2012

• Ohr Pharmaceutical to Present at Association for Research in Vision & Ophthalmology Annual Meeting on May 6, 2012

  5/3/2012

• Ohr Pharmaceutical Announces Ophthalmic Scientific Advisory Board

  5/1/2012

• Vista Partners Initiates Coverage on Ohr Pharmaceutical; Target Price $2.20

  4/17/2012

• arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel

  3/19/2012

• Regeneron Pharmaceuticals, Inc. Says Its Eye Drug is Taking Roche Patients

  3/16/2012

• Regeneron Pharmaceuticals, Inc. to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation

  1/3/2012

• Regeneron Pharmaceuticals, Inc. Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA(TM) (aflibercept) Injection

  1/3/2012

• Wolters Kluwer Pharma Solutions: inThought Report Says New Wave of Cardiology Drugs to be Big Boon

  12/20/2011